NDC 0069-1029

XELJANZ

Tofacitinib

XELJANZ is a Oral Solution in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Tofacitinib Citrate.

• Product ID: 0069-1029_109ebd67-7ce7-4c07-9101-3afd19cefd7b
• NDC: 0069-1029
• Product Type: Human Prescription Drug
• Proprietary Name: XELJANZ
• Generic Name: Tofacitinib
• Dosage Form: Solution
• Route of Administration: ORAL
• Marketing Start Date: 2021-02-08
• Marketing Category: NDA / NDA
• Application Number: NDA213082
• Labeler Name: Pfizer Laboratories Div Pfizer Inc
• Substance Name: TOFACITINIB CITRATE
• Active Ingredient Strength: 1 mg/mL
• Pharm Classes: Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0069-1029-02

1 BOTTLE in 1 CARTON (0069-1029-02) > 240 mL in 1 BOTTLE (0069-1029-01)

• Marketing Start Date: 2021-02-08
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "XELJANZ" or generic name "Tofacitinib"

NDC	Brand Name	Generic Name
0069-0501	XELJANZ	tofacitinib
0069-0502	XELJANZ	tofacitinib
0069-1001	XELJANZ	tofacitinib
0069-1002	XELJANZ	tofacitinib
63539-012	XELJANZ	XELJANZ
63539-016	XELJANZ	XELJANZ
0069-1029	XELJANZ	XELJANZ